Skip to main content

La medicina de precisión contra la resistencia a antimicrobianos: Proyecto MePRAM

PMP22/00092

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Call Proyectos de Investigación de Medicina Personalizada de Precisión
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER)
Execution centre CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular studies of phages-Klebsiella pneumoniae in mucoid environment: innovative use of mucolytic agents prior to the administration of lytic phages

  • Pacios, Olga
  • Blasco, Lucía
  • Ortiz-Cartagena, Concha
  • Bleriot, Inés
  • Fernández-García, Laura
  • López, María
  • Barrio-Pujante, Antonio
  • Fernández-Cuenca, Felipe
  • Aracil, Belén
  • Oteo-Iglesias, Jesús
  • Tomás, María
© 2023 Pacios, Blasco, Ortiz Cartagena, Bleriot, Fernández-García, López, Barrio-Pujante, Cuenca, Aracil, Oteo-Iglesias and Tomás. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Mucins are important glycoproteins that form a protective layer throughout the gastrointestinal and respiratory tracts. There is scientific evidence of increase in phage-resistance in the presence of mucin for some bacterial pathogens. Manipulation in mucin composition may ultimately influence the effectiveness of phage therapy. In this work, two clinical strains of K. pneumoniae (K3574 and K3325), were exposed to the lytic bacteriophage vB_KpnS-VAC35 in the presence and absence of mucin on a long-term co-evolution assay, in an attempt to mimic in vitro the exposure to mucins that bacteria and their phages face in vivo. Enumerations of the bacterial and phage counts at regular time intervals were conducted, and extraction of the genomic DNA of co-evolved bacteria to the phage, the mucin and both was performed. We determined the frequency of phage-resistant mutants in the presence and absence of mucin and including a mucolytic agent (N-acetyl L-cysteine, NAC), and sequenced them using Nanopore. We phenotypically demonstrated that the presence of mucin induces the emergence of bacterial resistance against lytic phages, effectively decreased in the presence of NAC. In addition, the genomic analysis revealed some of the genes relevant to the development of phage resistance in long-term co-evolution, with a special focus on the mucoid environment. Genes involved in the metabolism of carbohydrates were mutated in the presence of mucin. In conclusion, the use of mucolytic agents prior to the administration of lytic phages could be an interesting therapeutic option when addressing K. pneumoniae infections in environments where mucin is overproduced., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI19/00878 and PI22/00323 and co-funded by the European Union, and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC). (SEIMC, http://www.seimc.org/). This research was also supported by CIBERINFEC (CIBER21/13/00095) and by Personalized and precision medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092). MT was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). OP, LF-G, and ML were financially supported by the grants IN606A-2020/035, IN606B-2021/013, and IN606C-2022/002, respectively (GAIN, Xunta de Galicia). IB was financially supported by the pFIS program (ISCIII, FI20/00302)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

  • Hernando-Amado, Sara
  • Gomis-Font, María A
  • Valverde, José R.
  • Oliver, Antonio
  • Martínez Menéndez, José Luis
Ceftazidime-avibactam is a β-lactam/β-lactamase inhibitor combination restricted for the treatment of multidrug-resistant infections of Pseudomonas aeruginosa non-susceptible to ceftazidime and resistant to carbapenems. Crucially, it has not been studied if its use could allow the design or application of new or stablished evolution-based strategies that exploit the increased susceptibility that emerges when resistance is acquired (collateral sensitivity, CS). Works in the field have focused on the study of CS in model strains, but to be exploited it must robustly emerge in pre-existing resistant mutants that can coexist in a patient. This is the first analysis of CS robustness on this last-resort drug. We evolved 15 clinical isolates on ceftazidime-avibactam and in absence of inhibitor, and here we show that we found no robust -exploitable- pattern of CS. This, together with the selection of cross-resistance and the impossibility of using previously described CS-based strategies, supports that avibactam should be restricted for the treatment of particular genotypes., This work was supported by MICIU/AEI/10.13039/501100011033 and FEDER (UE) -grant PID2023-149913OA-I00- to S.H.A. and by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU -grants PI21/00017 and Personalized and precision medicine grant MePRAM Project PMP22/00092- to A.O. The MICIU/AEI/ 10.13039/501100011033 is also acknowledged for supporting the National Center for Biotechnology through the “Severo Ochoa” grant CEX2023-001386-S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phage Therapy for Bone and Joint Infections: Towards Clinical Translation

  • Ortiz-Cartagena, Concha
  • Blasco, Lucía
  • Bleriot, Inés
  • Esteban, Jaime
  • Toro, María Dolores del
  • Pozo, José Luis del
  • Tomás, María
This article belongs to the Special Issue Bone and Joint Infections: The Challenges of Prevention, Diagnosis and Treatment and Opportunities for Future Research., Osteoarticular infections (OAIs), including osteomyelitis, septic arthritis, prosthetic joint infections, and facture-related infections, remain a major challenge due to biofilm formation and the prevalence of multidrug-resistant (MDR) pathogens. Although OAIs are predominantly caused by Staphylococcus aureus and coagulase-negative staphylococci, the increasing incidence of MDR Gram-negative infections adds further complexity to their management. Standard approaches, combining surgery and prolonged antibiotic therapy, frequently result in recurrence and poor outcomes. Bacteriophage (phage) therapy has emerged as a promising adjunct or alternative approach, offering high host specificity, replication at the infection site, and activity against biofilm-embedded bacteria. This review highlights recent advances in phage therapy for OAIs, focusing on administration routes (intravenous, intra-articular, topical, and oral) and on novel pharmaceutical delivery systems such as hydrogels, bone cements, microparticles, nanoparticles, and implant coatings. Preclinical and early clinical studies have analyzed phage stability, controlled release, and the synergistic effects of combined phage/antibiotic therapy. However, challenges remain regarding standardization, immunogenicity, and regulatory approval. Nonetheless, phage therapy shows promise for clinical translation as an adjunct or alternative to conventional treatments for OAIs. Well-designed clinical trials are urgently needed to confirm the efficacy of phage therapy, optimize delivery strategies, and integrate the treatments in routine practice. Despite encouraging outcomes for a successful clinical implementation, regulation and standardization of GMP production are required., This study was funded by grant PI22/00323 awarded to M. Tomás and PI awarded to Rafael Cantón PI19/01043 within the State Plan for R + D + I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III FEDER, and by a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092 and COOPERA Project, COOP24CIII/00009), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGeneration European Union funds that support the actions of the Resilience and Recovery Facility., Peer reviewed